Skip to content

April 18, 2024
TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing
Webinar / Presentation
On May 15, join Treatment Action Group for a webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.

April 10, 2024
Treatment Action Group (TAG) seeks a highly motivated and organized Administrator to support the organization as it continues to grow. This position reports to TAG’s Director of Operations and Human Resources. This is a full-time, salaried position.

March 27, 2024
1/4/6×24 Mid-Campaign Report Launch Webinar
Webinar / Presentation
On March 27, 2024, the 1/4/6×24 Campaign and the Stop TB Partnership co-hosted a webinar to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments.

March 22, 2024
Mid-Campaign Report Highlights What’s Needed to Win Better, Shorter TB Treatments for All by End of 2024
Statement / Press
Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6×24 Campaign coalition has found.

March 21, 2024
Getting Better Faster: Delivering on the Promise of New TB Treatments – A Report from the 1/4/6×24 Campaign
This report marks the midway point of the 1/4/6×24 Campaign, which calls for the universal implementation of best available TB regimens — as little as one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.

March 18, 2024
Research in Action Awards 2024
Save the Date: Thursday, October 17, 2024, when our Research in Action Awards return this fall! Once again we’ll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV).

March 14, 2024
2024 CROI Tuberculosis Research Round Up
Statement / Press
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). The highlights presented here cover the results of several phase II TB prevention and treatment trials.

March 12, 2024
TB Project Associate
Treatment Action Group (TAG) is seeking a highly motivated and organized TB Project Associate to support TAG’s advocacy portfolio on tuberculosis (TB). This position will report to the TB Project Co-Director and be based in New York City.

March 11, 2024
Policy Issue Briefs: BARDA and ARPA-H
These two policy briefs explore two as yet untapped sources for drug-resistant tuberculosis (DR-TB) research funding within the U.S. Department of Health and Human Services (HHS).

February 29, 2024
TPT Community Materials
These free educational materials are designed for community-based and civil society organizations to use to advocate for and teach people about TB preventive treatment (TPT).

February 28, 2024
Washington D.C. Community Consensus on the Earlier Inclusion of Pregnant Women and Persons in TB Research
In October 2023, sixteen members of the global TB community developed a consensus statement on the inclusion of pregnant and breastfeeding women and persons in TB treatment and vaccines research.

February 14, 2024
TAG Announces New Board Leadership
Statement / Press
Treatment Action Group (TAG), the New-York-City-based activist research and policy think tank working to end the epidemics of HIV, TB, and hepatitis C, made leadership changes at its annual Board of Directors meeting on February 10, 2024.

January 30, 2024
Health Activist Groups: Defunding UNRWA in Gaza Is an Act of Depravity and Enables a Genocide
Statement / Press
We are appalled. As organisations that have historically worked on issues of health justice and access to medicines for millions of people around the world, for decades, focusing on HIV/AIDS, TB, cancer, and COVID, we share the urgent concern and outrage of aid organizations (NGOs) that the sudden decision by global north…

December 21, 2023
Statement from TAG, Global TB CAB on H56:IC31 Phase IIb Trial Results
Statement / Press
This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium tuberculosis antigens and the IC31 adjuvant made by Valneva.

December 5, 2023
Report: TB R&D Funding Perilously Off Track of UN Commitments to End Disease by 2030
Statement / Press
A new report released today by Treatment Action Group (TAG) and the Stop TB Partnership has found that cumulative funding for tuberculosis (TB) research and development (R&D) over the past five years is falling shockingly short of commitments.

Back To Top